Abstract

(1) Background: Pancreatic cancer is a high devastating disease with the lowest survival rate among all common cancers due to difficulties in early diagnosis. The purpose of this study was to identify and characterize the distinct subset of blood cell population elevated in peripheral blood mononuclear cells (PBMC) of pancreatic cancer to evaluate the potential markers for diagnosis of pancreatic cancer; (2) Methods: We analyzed differential gene expression in PBMC from normal individuals and pancreatic cancer patients utilizing transcriptome analysis. Flow cytometry analysis was applied to identify the discrete subset of interleukin-7 receptor (IL-7R) expressing cells in these cells. The expression of IL-7R during tumorigenesis was determined in syngeneic mouse model of pancreatic cancer in vivo; (3) Results: PBMC from pancreatic cancer patients expressed elevated IL-7R mRNA compared to healthy control individuals. IL-7R expressing cells rapidly appeared from the early stages of the onset of tumor formation in syngeneic pancreatic cancer mouse model in vivo. The discrete subset of IL-7R positive cells mainly consist of naive T, central memory T, and effector memory T cells; (4) Conclusions: Taken together, our present findings suggest that pancreatic cancer patients expressed higher level of IL-7R expression in PBMC that rapidly emerged from the onset of early pancreatic tumor formation in vivo than normal individuals. Thus, it can be used as a novel biological marker for early events of pancreatic cancer development.

Highlights

  • Statistical significance was analyzed based on sex but there was no statistical significance in normal healthy donors (p > 0.9586) or pancreatic cancer patients (p > 0.5365)

  • interleukin-7 receptor (IL-7R) expression was significantly up-regulated in peripheral blood mononuclear cells (PBMC) from pancreatic cancer patients in comparison of those of healthy

  • Elevated expression of Interleukin 7 (IL-7) and its signaling complex including Jak-3 and PI3-K is associated with aggressive human breast cancer [13] and IL-7 significantly accelerates the growth of breast cancer cells in vitro [15]

Read more

Summary

Introduction

Pancreatic cancer is one of the most aggressive malignancy with a five-year survival rate of as low as 10% at the time of diagnosis. This survival rate is significantly lower than the average survival rate of about 70% for all cancers. In cases of distant metastasis, the five-year survival in patients with pancreatic cancer decreases to less than 3% [1,2]. The low survival rate is attributed to several factors: (1) most patient with pancreatic cancer remain asymptomatic until the disease develops to an advanced stage.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call